Pharmaceutical industry – Page 25
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
-
BusinessUS probes opioid manufacturers
Attorneys general from 41 states will investigate companies over alleged fraudulent marketing and distribution of painkillers
-
FeaturePhotoredox: charge of the LED brigade
Forget fluorescent light bulbs, photochemistry has become a lot more sophisticated
-
BusinessTeva to sell off women’s health businesses for $1.4bn
Deals continue Teva’s bid to get rid of non-core businesses and raise cash to service its debts
-
BusinessAllergan sidesteps patent review with tribal deal
Native Americans agree to use sovereign immunity to protect intellectual property from double challenge
-
BusinessAlexion axes 20% of its global workforce
600 jobs lost amid restructure as firm moves to Boston life sciences hub
-
OpinionAn opportunity ignored
Dismissing ideas that were ‘not invented here’ is like walking past a $100 bill
-
BusinessTeva sells off contraceptive device in $1.1bn deal
CooperSurgical to acquire Paragard as Teva seeks to offload assets
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses
-
BusinessFDA warns Pfizer subsidiary over Epipen malfunctions
Manufacturer did not fully investigate reports of patients dying after auto-injector failures
-
BusinessEli Lilly to cut 3500 jobs
Company will close sites in US and China, and provide incentives for early retirement
-
ArticlePharma supply chains pick up pace
Contract suppliers are increasingly important in reducing time to market
-
BusinessAsia’s age of regulation
Safety legislation and data sharing in Asia is making progress but highlights a global challenge
-
ArticleIn-house training speeds up metabolism
Business plugs DMPK skills gap to improve drug discovery
-
-
-
BusinessMylan settles Epipen overcharging allegations
Company will pay US Department of Justice $465m for avoiding paying rebates to government healthcare systems
-
OpinionMake room for randomness in drug development
Setting free the dark horses sometimes beats the most rational planning
-
BusinessChemical and pharma bosses quit US manufacturing council
President Trump disbands the group after multiple advisers resign in protest against his stance on racism
-
WebinarCurrent topics in bioconjugation
Insights into making bioconjugates using optimal reagents and the latest techniques to create highly active and stable complexes